Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients

Journal of Clinical Virology

Volumn 61, Issue 2, 2014, Pages 199-203

  Li, Wenyu ^a   Huang, Ling ^a   Guo, Hanguo ^a   Wei, Xiaojuan ^a   Liang, Zhanli ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Antiviral therapy; HBsAg positive lymphoma; HBV reactivation; Telbivudine; Telbivudine concurrent with chemotherapy

Indexed keywords

ADEFOVIR DIPIVOXIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; FLUDARABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TELBIVUDINE; VINCRISTINE; VIRUS DNA; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; THYMIDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; YOUNG ADULT; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOCOMPROMISED PATIENT; TREATMENT OUTCOME; VIRUS ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYMIDINE; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84924029001     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.07.005     Document Type: Article

References (28)

1. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
2. Lu F.M., Zhuang H. Management of hepatitis B in China. Chin Med J (Engl) 2009, 122(1):3-4.
3. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K., Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
4. Alexopoulos C.G., Vaslamatzis M., Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evaluation of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 1999, 81:69-74.
5. Su W.P., Wen C.C., Hsiung C.A., Su I.J., Cheng A.L., Chang M.C., et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol 2005, 11(34):5283-5288.
6. Cheng A.L., Hsiung C.A., Su I.J., Chen P.J., Chang M.C., Tsao C.J., et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV carriers with lymphoma. Hepatology 2003, 37:1320-1328.
7. Shibolet O., IIan Y., Gillis S., Hubert A., Shouval D., Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002, 100:391-396.
8. Hsu C., Hsiung C.A., Su I.J., Hwang W.S., Wang M.C., Lin S.F., et al. A revisit of prophylactic lamivudine for chemotherapy associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853.
9. Yeo W., Chan P.K., Ho W.M., Zee B., Lam K.C., Lei K.I., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22:927-934.
10. Hui C.K., Cheung W.W.W., Au W.Y., Lie A.K.W., Zhang H.Y., Yueng Y.H., et al. Hepatitis B reactivation after withdrawl preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005, 54:1597-1603.
11. Standring D.N., Bridges E.G., Placidi L., Faraj A., Loi A.G., Pierra C., et al. Antiviral beta-l-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001, 12(Suppl. 1):119-129.
12. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl Med 2007, 357:2576-2588.
13. Lok A.S., McMahon B.J. Practice Guidelines Committee, American Association for the Study of Liver Disease (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004, 39(3):857-861.
14. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
15. Chen X.Q., Peng J.W., Lin G.N., Li M., Xia Z.J. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012, 29(2):1237-1241.
16. Huang Y.H., Hsiao L.T., Hong Y.C., Chiou T.J., Yu Y.B., Gau J.P., et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013, 31(22):2765-2772.
17. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients under going cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299-307.
18. Yeo W., Chan T.C., Leung N.W.Y., Lam W.Y., Mo F.K.F., Chu M.T., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
19. Seth P., Alrajhi A.A., Kagevi I., Chaudhary M.A., Colcol E., Sahovic E., et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002, 30:189-194.
20. Vento S., Cainelli F., Longhi M.S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002, 3:333-340.
21. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A one-year of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen positive chronic hepatitis B. Gastroenterology 2005, 129(2):528-536.
22. Liao C.A., Lee C.M., Wu H.C., Wang M.C., Lu S.N., Eng H.L. Lamivudine for the treatment of hepatitis B virus reactivation follow the chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002, 116:166-169.
23. Pei S.N., Chen C.H., Lee C.M., Wang M.C., Ma M.C., Hu H., et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010, 89(3):255-262.
24. Li Y.H., He Y.F., Jiang W.Q., Wang F.H., Lin X.B., Zhang L., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006, 106:1320-1325.
25. Colonno R.J., Rose R.E., Pokornowski K., Baldick C.T., Eggers B., Yu D., et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007, 46(suppl 1):s294.
26. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
27. Liang R., Lau G.K., Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17:394-398.
28. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S.F., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1724-1749.